Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection
- 2 April 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 102 (7), 746-754
- https://doi.org/10.1002/bjs.9775
Abstract
Background Randomized studies of adjuvant chemotherapy using gemcitabine suggest a survival benefit after resection of pancreatic cancer. S‐1 has also been shown to prolong survival in patients with unresectable pancreatic cancer. This study compared the effects of adjuvant chemotherapy with S‐1 or gemcitabine after resection of pancreatic cancer in a randomized trial. Methods Patients who had undergone resection of pancreatic cancer were registered in this randomized clinical trial. The primary endpoint was disease‐free survival (DFS). Expression levels of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNAs in cancer tissues were measured as indicators of fluoropyrimidine sensitivity. Results Of 57 patients registered, 29 were allocated to the S‐1 group and 28 to gemcitabine. DFS tended to be better with S‐1 (median 14·6 (90 per cent c.i. 8·8 to 28·4) months versus 10·5 (7·0 to 28·4) months in the gemcitabine group; P = 0·188), with a similar pattern for overall survival: 21·5 (95 per cent c.i. 14·4 to 42·3) and 18·0 (13·3 to 42·8) months respectively (P = 0·293). When patients were divided into subgroups based on high or low DPD and TS expression, those with a DPD level below the median of 0·88 or a TS level of at least 2·00 had a significant prolongation of DFS after S‐1 treatment compared with gemcitabine (P = 0·008 and P = 0·035 respectively). Conclusion Overall, S‐1 did not improve DFS compared with gemcitabine after pancreatic cancer resection, but there seemed to be a DFS advantage in patients with low expression of DPD or high expression of TS. Reference number: UMIN000009118 (http://www.umin.ac.jp/ctr/).Keywords
This publication has 18 references indexed in Scilit:
- Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 StudyJournal of Clinical Oncology, 2014
- Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancerBritish Journal of Cancer, 2013
- Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS studyAnnals of Oncology, 2012
- Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trialBritish Journal of Cancer, 2012
- Thymidylate Synthase and Dihydropyrimidine Dehydrogenase Are Upregulated in Pancreatic and Biliary Tract CancersPathobiology, 2009
- Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)Japanese Journal of Clinical Oncology, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJama-Journal Of The American Medical Association, 2007
- Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal CancerClinical Cancer Research, 2006
- Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequenceJournal of Gastrointestinal Surgery, 2000